NCT03310541View on ClinicalTrials.gov

AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 11, 2017

Primary Completion Date

May 3, 2023

Study Completion Date

May 3, 2023

Conditions
Breast CancerProstate CancerAdvanced Solid Tumors
Interventions
DRUG

AZD5363

AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week

DRUG

Enzalutamide

Enzalutamide 160 mg PO once daily

DRUG

Fulvestrant

500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks

Trial Locations (3)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

07748

Memorial Sloan Kettering Monmouth, Middletown

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03310541 - AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | Biotech Hunter | Biotech Hunter